U.S. markets open in 1 hour 9 minutes

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.3300+0.0700 (+3.10%)
At close: 4:00PM EDT

2.3900 +0.06 (2.58%)
Pre-Market: 8:00AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close2.2600
Bid2.3600 x 1300
Ask2.4500 x 1000
Day's Range2.1800 - 2.3300
52 Week Range0.7300 - 3.1300
Avg. Volume1,330,809
Market Cap365.302M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.3730
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lineage Cell Delivers Lower-than-Feared Q1 Loss; Shares Pop 5%

    Lineage Cell Delivers Lower-than-Feared Q1 Loss; Shares Pop 5%

    Shares of Lineage Cell Therapeutics, Inc. (LCTX) rose 5% in Thursday’s extended trading session after the biotechnology company reported a smaller-than-expected loss in the first quarter. The company develops novel cell therapies for unmet medical needs. Lineage Cell reported a loss of $0.01 per share in Q1 compared to the $0.06 loss per share recorded in the year-ago quarter. Analysts were expecting the company to report a loss of $0.03 per share. Total revenues were $0.39 million in Q1 versus analysts’ expectations of $0.35 million. Top line figures were down 24% year-over-year. Research and development expenses increased 3% year-over-year to $3.4 million, while general and administrative costs decreased 13.3% to $3.9 million. (See Lineage Cell Therapeutics stock analysis on TipRanks) Lineage CEO Brian M. Culley said, “We remain encouraged by the totality of the OpRegen clinical data presented to date, which is suggestive of clinically meaningful benefits, especially in earlier stage disease dry-AMD patients. Moreover, the strategic collaborations we announced for OPC1 and VAC reflect our commitment to a comprehensive asset management approach and add external validation to the potential of our platform to create positive outcomes for patients.” Last month, Cantor Fitzgerald analyst Kristen Kluska reiterated a price target of $6 (176.5% upside potential) and a Buy rating on the stock. Kluska believes that the company’s efforts to evaluate OpRegen for the treatment of dry-AMD with geographic atrophy, OPC1 for spinal cord injuries, and VAC2 for cancer, have “demonstrated transformational benefits” across its two lead programs. These initiatives along with solid execution could lead to upside potential in shares over the next 12 months, the analyst added. Consensus among analysts is a Strong Buy based on 5 Buys and 1 Hold. The average analyst price target stands at $4.75 and implies upside potential of 118.9% to current levels. Shares have gained 152.3% over the past year. Related News: Alaska Air Expanding Fleet With 30 Mainline And Regional Aircraft HEXO Teams Up With REQ On Brand Expansion In U.S. XPeng’s Quarterly Revenue Jumps 6X, Vehicle Deliveries Up Almost 5X More recent articles from Smarter Analyst: Airbnb Reports Mixed Q1 Results As Travel Rebounds; Street Sees 44.8% Upside INDUS Realty Snaps Up Logistics Building In Pennsylvania For $11.7M McGrath RentCorp to Snap up Design Space Modular Buildings for $260M Floor & Decor Inks $90M Deal To Snap Up Spartan Surfaces

  • Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript
    Motley Fool

    Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript

    This call is subject to copyright and is the property of Lineage and recordings, reproduction, or transmission of this call without the expressed written consent of Lineage are strictly prohibited. Thank you, Mary.

  • Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates

    Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates

    Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -63.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?